With a median follow up of 71 months, the 5-year actuarial biochemical recurrence-free survival rates of patients who did and did not receive neoadjuvant hormonal therapy were 92.9% and 93.6%, respectively (P = 0.2843). When patients were stratified by risk group, neoadjuvant hormonal therapy did not improve biochemical recurrence-free survival outcomes in low-(P = 0.8949) or intermediate-risk (P = 0.1989) patients. The duration or type of hormonal therapy was not significant in predicting biochemical recurrence. In a multivariate analysis, Gleason score, pretreatment prostate-specific antigen, clinical T stage, and prostate dosimetry, primary Gleason score and positive core rate were significant predictive factors of biochemical recurrence-free survival, whereas neoadjuvant hormonal therapy was insignificant. Furthermore, neoadjuvant hormonal therapy did not significantly influence progression-free survival, cancer-specific survival or overall survival. Conclusions: In patients with low-or intermediate-risk disease treated with permanent prostate brachytherapy, neoadjuvant hormonal therapy does not improve oncological outcomes. Its use should be restricted to patients who require prostate volume reduction.
Introduction
Permanent brachytherapy is a standard treatment for patients with localized prostate cancer. 1 It is indicated for low-risk prostate cancer and in select patients with low-volume, intermediate-risk cancers, and is often used in association with NHT not only to reduce the volume of the prostate, but also to improve the oncological outcome in patients with higher-risk features. [2] [3] [4] Several reports have shown that hormonal therapy combined with radiotherapy improves oncological outcomes in patients with "locally advanced" prostate cancer, whereas the use of hormonal therapy in patients with localized prostate cancer remains controversial.
efficacy of NHT has not yet been established for patients with either low-or intermediate-risk disease. In the present study, we assessed the oncological outcomes of NHT in patients with low-or intermediate-risk prostate cancer undergoing permanent brachytherapy.
Methods
Between January 2004 and November 2014, 564 patients with localized prostate cancer underwent transperineal ultrasonography-guided permanent 125 I seed brachytherapy at Okayama University Hospital. Based on NCCN guidelines, we defined the indications for permanent brachytherapy as low-risk disease (PSA <10 ng/mL and Gleason score ≤6 and cT ≤T2a), intermediate-risk disease (PSA 10-20 ng/mL or Gleason score 7 or cT T2b-T2c) and high-risk disease (PSA >20 ng/mL or Gleason score >8 or cT ≥T3a). Of the 564 patients, 21 patients with high-risk disease, 53 patients who had not been followed up for >2 years, four patients who received adjuvant hormonal therapy and two patients who had incomplete records were excluded from this study. We analyzed 484 patients with a minimum follow up of 2 years. To determine each patient's disease classification, all pathology slides of biopsy specimens from all patients were thoroughly reviewed by one pathologist (HY) with genitourinary expertise at Okayama University Hospital, Okayama, Japan.
In our Okayama University Hospital, when the prostate volume was >35 mL or an adequate dose-volume histogram could not be calculated in patients with pubic arch interference, NHT was administered for 3 months as a general rule. If the prostate was not sufficiently reduced, an additional 3-month course of NHT was administered. NHT was given to four patients with intermediate-risk disease in the context of a clinical trial (SHIP0804, NCT00664456), and to 64 patients who needed to wait for several months to undergo brachytherapy at the discretion of their urologist.
The pre-planning outpatient procedure was usually carried out 1 month before seed implantation using the Variseed 7.1 system (Varian Medical System, Palo Alto, CA, USA). During pre-planning, transrectal ultrasound, which allows volumetric analysis of the prostate gland, was carried out in the dorsal lithotomy position. Seed implantation was carried out under spinal anesthesia. Seeds were placed one-by-one transperitoneally through the needles using a Mick Applicator (Mick Radio-Nuclear Instruments, Mount Vernon, NY, USA). A prescribed dose of 144 Gy was planned to cover >95% of the planning target volume (prostate with 0-3-mm margins). Prostate dosimetry was obtained by a radiation oncologist based on day 30 post-implant computed tomography using Variseed software. The prostate D90 was recorded. The treatment procedure has been described previously. 8, 9 Patients were followed routinely with PSA measurements every 3 months for 1 year, then every 6 months for an additional 4 years, and annually thereafter. BCR was defined based on the 2006 Radiation Therapy Oncology-American Society for Radiation Oncology Phoenix Consensus definition (nadir PSA + 2 ng/mL). 10 Progression was defined as any recurrence at a primary site or any metastasis in imaging studies.
BRF survival, PFS, CSS 11 and OS were calculated using the Kaplan-Meier method, and the log-rank test was used for univariate analysis to compare BRF survival rates. Cox regression analysis was used for multivariate analysis. Clinical variables evaluated for influence on BRF survival included use of NHT, Gleason score, clinical T stage, NCCN risk group, radiation dose, pretreatment PSA, primary Gleason score and positive core rate. For all tests, a P-value of <0.05 was considered statistically significant. The JMP version 10 statistical package (SAS Institute, Cary, NC, USA) was used for data analysis. This study was approved by the institutional review board of our hospital (IRB#1710-007). Written informed consent was obtained from all patients before the initiation of treatment.
Results
Patient characteristics are shown in Table 1 . Of the 484 patients analyzed, 259 presented with low-risk disease and 225 presented with intermediate-risk disease based on the NCCN classification. The median age at seed implantation was 67 years (IQR 62-71 years), median PSA value before biopsy was 6.7 ng/mL (IQR 5.1-9.0 ng/mL) and median duration of follow up was 71 months (IQR 48-95 months).
NHT was carried out in 188 patients, and the median duration of NHT was 3 months (IQR 3-6 months). Of them, the median of prostate volume before and after hormonal therapy was 36.4 mL and 25.0 mL, respectively (a 33.1% reduction); the NHT+ group had a significantly higher PSA and larger prostate volume, but lower positive core rate ( The 5-and 10-year BRF survival rates of patients who did not receive NHT were 92.9% and 72.3%, respectively, and those for patients who received NHT were 93.7% and 77.0%, respectively. No statistically significant differences in BRF survival rates were observed between groups (P = 0.2843) or among patients with low-risk and intermediate-risk disease, respectively (P = 0.8949 and 0.1989; Fig. 1 ). Furthermore, neither duration (≤3 months vs >3 months, P = 0.1961) nor type of hormonal therapy (single LH-RH agonist or anti-androgen vs CAB, P = 0.3708) was significantly associated with biochemical failure. In a multivariate analysis, Gleason score, pretreatment PSA, clinical T stage, and prostate dosimetry (prostate D90), primary Gleason score and percentage of positive cores were significant predictive factors of BRF survival, whereas NHT was insignificant (Table 2) . When limiting to the intermediaterisk group, Gleason score, T stage and primary Gleason score were identified as significant factors for predicting BCR in multivariate analysis, whereas NHT was not identified as a predictive factor in either type of analysis (Table 3) . For the entire cohort, the 5-and 10-year PFS rates for patients who did not receive NHT were 98.1% and 86.1%, respectively, and those for patients who received NHT were 98.0% and 94.4%, respectively (P = 0.1469). The 5-and 10-year OS rates for patients who did not receive NHT were 96.9% and 89.8%, respectively, and those for patients who received NHT were 100% and 91.5%, respectively (P = 0.1872). Three patients died of prostate cancer; 10-year CSS rates were 98.5% and 95.7% in patients who did not and did receive NHT, respectively (P = 0.9430). Several retrospective studies showed that the use of NHT for 3-6 months was not a significant predictor of the biochemical failure-free rate in patients with low-risk or intermediate-risk prostate cancer.
3,12-14 Our previous retrospective study with a median follow-up period of 36.5 months also showed that NHT for volume reduction was not associated with BCR (P = 0.6109). 15 Furthermore, Henry et al. showed that intermediate-risk patients who received 3-4 months of NHT had poorer biochemical failure-free rates compared with those who did not receive NHT (10-year rate, 70.0% vs 79.4%, P = 0.04). 16 In their series, these investigators described the presence of confounding factors associated with higher-risk pathological features, such as Gleason score 4 + 3 or higher percentages of positive cores. Our previous study suggested that primary Gleason grade 4 was a significant predictor of biochemical failure in patients with intermediate-risk prostate cancer. 15 In the present study, the NHT+ group had a significantly lower positive core rate (Table 1) . Although a positive core rate was significantly associated with BCR in univariate analysis, it was not one of the predictors for BCR in multivariate analysis (Tables 2,3 ). In contrast, Lee et al. reported 5-year BRF survival rates in high-risk patients treated without and with hormone therapy of 74% and 46%, respectively (P < 0.001), and that hormonal therapy was identified as a significant factor for improving BCR in multivariate analysis. These results were supported by a study carried out by Merric et al., in which hormonal therapy resulted in clinically superior biochemical outcomes when high-risk patients were stratified only by hormonal therapy status. 17, 18 To describe oncological outcomes, we should focus on CSS and OS in addition to BCR. Beyer et al. compared CSS and OS in patients who underwent brachytherapy with NHT (n = 464) versus without NHT (n = 1884). 19 With a median follow-up period of 4.1 years, the OS of patients who received NHT was significantly shorter than that of those who did not receive NHT, whereas CSS did not significantly differ between groups. Furthermore, multivariate analysis showed that use of hormonal therapy was an independent predictor of worse survival. Of note, duration of NHT was ≤6 months in 80% in their cohort. These authors suggested that the leading cause of death was cardiovascular disease in both groups, and that systemic effects of NHT might have a detrimental effect on OS. Dosoretz et al. showed that NHT for 3-6 months with the aim of prostate volume reduction before brachytherapy increased the risk of all-cause mortality in patients aged ≥73 years, but not in those aged <73 years. 20 Although the causes of death were not available, the researchers suggested these observations might be related to the adverse effects of hormonal therapy on the cardiovascular system. A large retrospective study including 5411 men with low-risk prostate cancer and 4365 men with intermediate-risk prostate cancer showed that NHT use significantly increased the risk of all-cause mortality in patients with low-risk disease, but not in those with intermediate-risk disease. Interestingly, this association was not valid in men without any coronary artery disease risk factors, a history of diabetes mellitus, hypercholesterolemia or hypertension. 21 In the majority of patients with early prostate cancer, the natural history of the disease suggests a relatively lower risk of dying. For these patients, the risks of hormonal intervention might be greater than the small benefit that may accompany treatment. Therefore, we should keep in mind short-term NHT be potential for these adverse effects.
NHT for volume reduction is required more frequently in Japan than in Western countries, because just 1300 MBq of 125 I might be implanted in any given individual due to unique laws in Japan. NHT has been used to reduce prostate volume in our institution, particularly for patients with unfavorable geometry (pubic arch interference) or with a large prostate volume. 8, 22 Ebara et al. examined the prostate volume reduction rate based on the duration and type of hormonal therapy, and suggested prostate volumes ≤60 mL could be reduced to an appropriate size with 3 months of LH-RH agonist therapy. 8 Although the purpose of NHT before brachytherapy is prostate volume reduction, it is also expected to enhance radiation therapy efficacy, especially when combined with EBRT. 17 Stone et al. showed that another advantage of NHT was that it significantly reduced the risk of urinary retention for patients with moderate-tosevere urinary symptoms before brachytherapy. 4 In contrast, NHT has often made implanting seeds difficult, resulting in worse prostate D90s. 23 Furthermore, even with short-term use, NHT might be associated with an increased risk of diabetes and cardiovascular disease, and could have a significant effect on long-term sexual function. Potters et al. reported that the 5-year potency rate for patients treated with permanent prostate brachytherapy as monotherapy was 76%; those treated with combination NHT and permanent brachytherapy had a 5-year potency rate of 52%. Multivariate analysis showed that NHT predicted impotence. 24 Although permanent brachytherapy is fundamentally advantageous to preserve sexual function, this effect might be compromised by hormonal therapy.
An ongoing prospective randomized study (SHIP0804), in which patients with untreated intermediate-risk prostate cancer in both arms receive 3 months of NHT to facilitate recruitment and reduce potential bias in patient selection, is evaluating the safety and efficacy of 9 months of adjuvant hormonal therapy compared with no adjuvant hormonal therapy. 25 Another ongoing prospective randomized study (RTOG0815) is comparing the OS for patients with intermediate-risk prostate cancer who do and do not receive shortterm (6-month) androgen deprivation therapy consisting of an LH-RH agonist and oral anti-androgen therapy starting 8 weeks before dose-escalated radiotherapy with/without brachytherapy. However, no prospective randomized controlled trials have documented the efficacy and safety of NHT before brachytherapy.
Recently, the indication for robot-assisted radical prostatectomy for localized prostate cancer has been extended, and active surveillance for low-risk prostate cancer has been accepted worldwide; therefore, utilization of radiation therapy, especially brachytherapy, has declined. 26, 27 However, radiation therapy is still the most frequently utilized treatment modality for patients aged ≥75 years with intermediate-risk prostate cancer. 27 The present study, which included relatively long-term follow up, did not find any oncological benefit of NHT before brachytherapy, but it should be noted that brachytherapy alone yielded excellent oncological outcomes.
The present study had several limitations. First, it was a relatively small and retrospective study. Second, the indication for NHT varied, although in two-thirds of cases NHT was carried out only for the prostate volume reduction. Third, the duration and type of NHT varied. Fourth, we did not evaluate quality of life or cardiovascular events related with NHT in the present study.
In conclusion, no oncological advantage of NHT associated with permanent brachytherapy was shown in patients with low-risk or intermediate-risk prostate cancer. In addition, neither the duration nor type of hormonal therapy was significantly associated with oncological outcome. Although other effects of NHT were not evaluated, its use should be restricted to patients who require prostate volume reduction.
